Company profile

Future of Fresenius

#
Rank
348
| Quantumrun Global 1000

Fresenius SE & Co. KGaA is a European Healthcare company that offers products and services for dialysis, hospitals as well as inpatient and outpatient medical care. It is based in Bad Homburg, Germany. It focuses on hospital management as well as engineering and services for medical centers and other healthcare facilities.

Home Country:
Sector:
Industry:
Healthcare - Medical Facilities
Website:
Founded:
1912
Global employee count:
232873
Domestic employee count:
Number of domestic locations:

Financial Health

Revenue:
$17911000000 EUR
3y average revenue:
$16826871000 EUR
Operating expenses:
$3040000000000 EUR
3y average expenses:
$1015179872667 EUR
Funds in reserve:
$1044000000 EUR
Revenue from country
0.48
Revenue from country
0.37

Asset Performance

  1. Product/Service/Dept. name
    Medical care
    Product/Service revenue
    16738000000
  2. Product/Service/Dept. name
    Kabi
    Product/Service revenue
    5950000000
  3. Product/Service/Dept. name
    Helios
    Product/Service revenue
    1189000000

Innovation assets and Pipeline

Global brand rank:
350
Investment into R&D:
$162364000 EUR
Total patents held:
623

All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page. 

DISRUPTION VULNERABILITY

Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations. *However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.
*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.
*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.
*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.
*Increasingly, we will use artificial intelligence systems diagnose patients and robots to manage intricate surgeries.
*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.
*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.

COMPANY’S FUTURE PROSPECTS

Company Headlines